Insmed (INSM) Cash from Operations Growth (3y) (2013 - 2026)
Insmed (INSM) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 34.32% |
| 10 | Insmed | 22.76 Bn | 21.53 Bn | 258.54 Mn | -15.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.04% |
| Dec 31, 2025 | -33.89% |
| Sep 30, 2025 | -34.75% |
| Jun 30, 2025 | -26.19% |
| Mar 31, 2025 | -35.58% |
| Dec 31, 2024 | -32.56% |
| Sep 30, 2024 | -33.85% |
| Jun 30, 2024 | -17.68% |
| Mar 31, 2024 | -12.78% |
| Dec 31, 2023 | -25.12% |
| Sep 30, 2023 | -32.45% |
| Jun 30, 2023 | -50.60% |
| Mar 31, 2023 | -36.18% |
| Dec 31, 2022 | -32.44% |
| Sep 30, 2022 | -19.71% |
| Jun 30, 2022 | -8.53% |
| Mar 31, 2022 | -12.51% |
| Dec 31, 2021 | -6.24% |
| Sep 30, 2021 | -4.83% |
| Jun 30, 2021 | -11.17% |